An observational, prospective, open label, multicenter study to evaluate the safety and effectiveness of pegfilgrastim as secondary prophylaxis to decrease the incidence of febrile neutropenia in Korean female patients with breast cancer

An observational, prospective, open label, multicenter study to evaluate the safety and effectiveness of pegfilgrastim as secondary prophylaxis to decrease the incidence of febrile neutropenia in Korean female patients with breast cancer

Purpose: Pegfilgrastim is a widely used long-acting granulocyte colony-stimulating factor (G-CSF) that prevents febrile neutropenia (FN) in patients with breast cancer receiving chemotherapy. This study aimed to evaluate the incidence of chemotherapy-related FN events and other adverse events (AEs)...

Full description

Bibliographic Details
Main Authors: Anbok Lee, Taewoo Kang, Su Hwan Kang, Woo-Chan Park, Woosung Lim, Myung-Chul Chang, Hyun Yul Kim, Jeong-yoon Song, Jihyoun Lee, Kyung Do Byun, Hyun-Ah Kim, Gil Soo Son, Ju-Yeon Kim, Se Jeong Oh, Min Sung Chung, Young Jin Choi, Hyuk-Jai Shin, Jong Min Baek, Youngbum Yoo, Eunhae Um, Jin Hyuk Choi, Beom Seok Kwak, Min Ho Park, Suok Hyun Lee, Cheol Seung Kim, Ilkyun Lee, Je-Ryong Kim, Han Shin Lee, Cheol Wan Lim
Format: Article
Language:English
Published: Elsevier 2023-12-01
Series:Breast
Online Access:http://www.sciencedirect.com/science/article/pii/S0960977623005611

Internet

http://www.sciencedirect.com/science/article/pii/S0960977623005611

Similar Items